JP2020535138A - グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト - Google Patents

グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト Download PDF

Info

Publication number
JP2020535138A
JP2020535138A JP2020516798A JP2020516798A JP2020535138A JP 2020535138 A JP2020535138 A JP 2020535138A JP 2020516798 A JP2020516798 A JP 2020516798A JP 2020516798 A JP2020516798 A JP 2020516798A JP 2020535138 A JP2020535138 A JP 2020535138A
Authority
JP
Japan
Prior art keywords
bound
lys
alpha
fatty
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020516798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535138A5 (cg-RX-API-DMAC10.html
Inventor
パラニ，アナンダン
デン，シャオリン
ヒュアン，チュンフェイ
ビアンキ，エリザベッタ
オルヴィエート，フェデリカ
ジュウ，ユーピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of JP2020535138A publication Critical patent/JP2020535138A/ja
Publication of JP2020535138A5 publication Critical patent/JP2020535138A5/ja
Priority to JP2023032146A priority Critical patent/JP2023071869A/ja
Priority to JP2023144460A priority patent/JP2023171744A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2020516798A 2017-09-25 2018-09-21 グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト Pending JP2020535138A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023032146A JP2023071869A (ja) 2017-09-25 2023-03-02 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2023144460A JP2023171744A (ja) 2017-09-25 2023-09-06 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562674P 2017-09-25 2017-09-25
US62/562,674 2017-09-25
PCT/US2018/052124 WO2019060660A1 (en) 2017-09-25 2018-09-21 CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023032146A Division JP2023071869A (ja) 2017-09-25 2023-03-02 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2023144460A Division JP2023171744A (ja) 2017-09-25 2023-09-06 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト

Publications (2)

Publication Number Publication Date
JP2020535138A true JP2020535138A (ja) 2020-12-03
JP2020535138A5 JP2020535138A5 (cg-RX-API-DMAC10.html) 2021-10-07

Family

ID=65810991

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020516798A Pending JP2020535138A (ja) 2017-09-25 2018-09-21 グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト
JP2023032146A Pending JP2023071869A (ja) 2017-09-25 2023-03-02 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2023144460A Pending JP2023171744A (ja) 2017-09-25 2023-09-06 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023032146A Pending JP2023071869A (ja) 2017-09-25 2023-03-02 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2023144460A Pending JP2023171744A (ja) 2017-09-25 2023-09-06 グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト

Country Status (11)

Country Link
US (1) US11566057B2 (cg-RX-API-DMAC10.html)
EP (1) EP3700550A4 (cg-RX-API-DMAC10.html)
JP (3) JP2020535138A (cg-RX-API-DMAC10.html)
KR (1) KR102505628B1 (cg-RX-API-DMAC10.html)
CN (1) CN111132690A (cg-RX-API-DMAC10.html)
AU (1) AU2018338184B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020005841A8 (cg-RX-API-DMAC10.html)
CA (2) CA3220650A1 (cg-RX-API-DMAC10.html)
MA (1) MA50474A (cg-RX-API-DMAC10.html)
MX (1) MX2020003217A (cg-RX-API-DMAC10.html)
WO (1) WO2019060660A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022004872A (es) * 2019-10-22 2022-05-13 Nuritas Ltd Tratamiento de enfermedad de higado graso no alcoholico.
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR20240043778A (ko) * 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
EP4724472A2 (en) * 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523659A (ja) * 2003-04-16 2006-10-19 セルテック アール アンド ディ リミテッド ケモカイン受容体の調節物質としての環式第四級アミノ誘導体
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1891105B1 (en) 2005-06-13 2012-04-11 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
JP6581656B2 (ja) * 2014-10-24 2019-09-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
EP3430033A4 (en) 2016-03-18 2019-11-20 Merck Sharp & Dohme Corp. CONJUGATES OF INSULIN-INCRETIN

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523659A (ja) * 2003-04-16 2006-10-19 セルテック アール アンド ディ リミテッド ケモカイン受容体の調節物質としての環式第四級アミノ誘導体
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors

Also Published As

Publication number Publication date
AU2018338184B2 (en) 2023-04-13
RU2020114220A3 (cg-RX-API-DMAC10.html) 2021-12-28
WO2019060660A1 (en) 2019-03-28
JP2023071869A (ja) 2023-05-23
MX2020003217A (es) 2020-07-29
RU2020114220A (ru) 2021-10-27
US11566057B2 (en) 2023-01-31
EP3700550A4 (en) 2022-02-23
EP3700550A1 (en) 2020-09-02
KR20200057059A (ko) 2020-05-25
CA3076496A1 (en) 2019-03-28
KR102505628B1 (ko) 2023-03-02
JP2023171744A (ja) 2023-12-05
CA3220650A1 (en) 2019-03-28
US20200270325A1 (en) 2020-08-27
BR112020005841A2 (pt) 2020-11-17
CN111132690A (zh) 2020-05-08
BR112020005841A8 (pt) 2023-04-11
MA50474A (fr) 2020-09-02
AU2018338184A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
JP6581656B2 (ja) グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
US11773150B2 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US11492385B2 (en) Long-acting co-agonists of the glucagon and GLP-1 receptors
CN115226391A (zh) 胰高血糖素和glp-1受体的钉合三唑共激动剂
RU2779314C2 (ru) Коагонисты рецепторов глюкагона и glp-1 длительного действия
EP4081244B1 (en) Stapled olefin co-agonists of the glucagon and glp-1 receptors
CN114867742A (zh) 胰高血糖素和glp-1受体的钉合内酰胺共激动剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230913

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231102